Introduction to the IQ Consortium and the IQ Clinical Pharmacology Leadership Group

DOI
  • Chunze Li
    Genentech; Chair of IQ Clinical Pharmacology Leadership Group
  • Mindy Magee
    GlaxoSmithKline (GSK); Vice Chair of IQ Clinical Pharmacology Leadership Group
  • Islam Younis
    Gilead; Secretary of IQ Clinical Pharmacology Leadership Group
  • Lee Nagao
    Faegre Drinker Biddle & Reath LLP; IQ Secretariat

抄録

<p>The International Consortium for Innovation and Quality in Pharmaceutical Development (the "IQ Consortium") is a not-for-profit organization of pharmaceutical and biotechnology companies with the mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader R&D community. The Consortium consists of several leadership groups that initiate workstreams addressing key areas of pharmaceutical development. The IQ Clinical Pharmacology Leadership Group (the "CPLG") is one of these groups. Over the years, the CPLG has initiated efforts addressing critical aspects of innovative clinical study design, MABEL, QTc, digital biomarkers, QSP, MIDD, and others. Through its working groups, the CPLG collaborates with other leadership groups within IQ, as well as other industry organizations and regulatory agencies. The CPLG and its working groups regularly present their findings to regional regulatory agencies. This presentation will provide background on IQ and the CPLG, and information on current and emerging consortium and CPLG activities.</p>

収録刊行物

詳細情報 詳細情報について

  • CRID
    1390857512439647360
  • DOI
    10.50993/jsptsuppl.43.0_2-c-s18-1
  • ISSN
    24365580
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ